HPV and RAD51 as Prognostic Factors for Survival in Inoperable
Oral and Oropharyngeal Cancer in Patients Unfit for
Chemotherapy Treated with Hyperfractionated Radiotherapy

J 2023

HPV and RAD51 as Prognostic Factors for Survival in Inoperable Oral and Oropharyngeal Cancer in Patients Unfit for Chemotherapy Treated with Hyperfractionated Radiotherapy

ZDEBLOVA CERMAKOVA, Zuzana, Pavel HURNÍK, David KONVALINKA, Jan STEMBIREK, Tereza PARACKOVA et. al.

Základní údaje

Originální název

HPV and RAD51 as Prognostic Factors for Survival in Inoperable Oral and Oropharyngeal Cancer in Patients Unfit for Chemotherapy Treated with Hyperfractionated Radiotherapy

Autoři

ZDEBLOVA CERMAKOVA, Zuzana (203 Česká republika), Pavel HURNÍK (203 Česká republika, garant, domácí), David KONVALINKA (203 Česká republika), Jan STEMBIREK (203 Česká republika), Tereza PARACKOVA, Kamila RESOVA (203 Česká republika), Jakub CVEK (203 Česká republika), Tomas BLAZEK (203 Česká republika), Lukas KNYBEL (203 Česká republika), Martin FORMANEK (203 Česká republika), Mariam GACHECHILADZE, Markus JOERGER, Alex SOLTERMANN, Jozef SKARDA, Oldrich MOTYKA (203 Česká republika) a Jana JANOUTOVA (203 Česká republika)

Vydání

Medicina-Lithuania, Basel, MDPI, 2023, 1010-660X

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30204 Oncology

Stát vydavatele

Švýcarsko

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Impakt faktor

Impact factor: 2.600 v roce 2022

Kód RIV

RIV/00216224:14110/23:00130670

Organizační jednotka

Lékařská fakulta

DOI

http://dx.doi.org/10.3390/medicina59020361

UT WoS

000939961000001

Klíčová slova anglicky

oropharyngeal cancer; oral cavity cancer; HPV; RAD51; radiotherapy

Štítky

14110517, rivok

Změněno: 8. 3. 2024 12:21, Mgr. Tereza Miškechová

Anotace

V originále

Introduction: The incidence of advanced oral cavity and oropharyngeal cancers is generally high. Treatment outcomes for patients, especially those unfit for comprehensive cancer treatment, are unsatisfactory. Therefore, the search for factors to predict response to treatment and increase overall survival is underway. Objective: This study aimed to analyze the presence of 32 HPV genotypes in tumor samples of 34 patients and the effect of HPV status and RAD51 on overall survival. Method: Tumor samples of 34 patients with locally advanced oropharyngeal or oral cavity cancer treated with accelerated radiotherapy in monotherapy were analyzed using reverse hybridization and immunohistochemistry for the presence of HPV and RAD51. Its effect on overall survival was examined. Results: Only two types of HPV were identified-HPV 16 (dominant) and HPV 66 (two samples). The HPV positivity was associated with a borderline insignificant improvement in 2-year (p = 0.083), 5-year (p = 0.159), and overall survival (p = 0.083). Similarly, the RAD51 overexpression was associated with borderline insignificant improvement in 2-year (p = 0.083) and 5-year (p = 0.159) survival. Conclusion: We found no statistically significant differences but detected trends toward improvement in the survival of HPV-positive and RAD51 overexpressing patients unfit for surgical treatment or chemotherapy treated with hyperfractionated radiotherapy. The trends, however, indicate that in a larger group of patients, the effects of these two parameters would likely be statistically significant.

Citovat

ZDEBLOVA CERMAKOVA, Zuzana, Pavel HURNÍK, David KONVALINKA, Jan STEMBIREK, Tereza PARACKOVA, Kamila RESOVA, Jakub CVEK, Tomas BLAZEK, Lukas KNYBEL, Martin FORMANEK, Mariam GACHECHILADZE, Markus JOERGER, Alex SOLTERMANN, Jozef SKARDA, Oldrich MOTYKA a Jana JANOUTOVA. HPV and RAD51 as Prognostic Factors for Survival in Inoperable Oral and Oropharyngeal Cancer in Patients Unfit for Chemotherapy Treated with Hyperfractionated Radiotherapy. Medicina-Lithuania. Basel: MDPI, 2023, roč. 59, č. 2, s. 1-12. ISSN 1010-660X. Dostupné z: https://dx.doi.org/10.3390/medicina59020361.

@article{2278259,
   author = {Zdeblova Cermakova, Zuzana and Hurník, Pavel and Konvalinka, David and Stembirek, Jan and Parackova, Tereza and Resova, Kamila and Cvek, Jakub and Blazek, Tomas and Knybel, Lukas and Formanek, Martin and Gachechiladze, Mariam and Joerger, Markus and Soltermann, Alex and Skarda, Jozef and Motyka, Oldrich and Janoutova, Jana},
   article_location = {Basel},
   article_number = {2},
   doi = {http://dx.doi.org/10.3390/medicina59020361},
   keywords = {oropharyngeal cancer; oral cavity cancer; HPV; RAD51; radiotherapy},
   language = {eng},
   issn = {1010-660X},
   journal = {Medicina-Lithuania},
   title = {HPV and RAD51 as Prognostic Factors for Survival in Inoperable Oral and Oropharyngeal Cancer in Patients Unfit for Chemotherapy Treated with Hyperfractionated Radiotherapy},
   url = {https://www.mdpi.com/1648-9144/59/2/361},
   volume = {59},
   year = {2023}
}

TY  - JOUR
ID  - 2278259
AU  - Zdeblova Cermakova, Zuzana - Hurník, Pavel - Konvalinka, David - Stembirek, Jan - Parackova, Tereza - Resova, Kamila - Cvek, Jakub - Blazek, Tomas - Knybel, Lukas - Formanek, Martin - Gachechiladze, Mariam - Joerger, Markus - Soltermann, Alex - Skarda, Jozef - Motyka, Oldrich - Janoutova, Jana
PY  - 2023
TI  - HPV and RAD51 as Prognostic Factors for Survival in Inoperable Oral and Oropharyngeal Cancer in Patients Unfit for Chemotherapy Treated with Hyperfractionated Radiotherapy
JF  - Medicina-Lithuania
VL  - 59
IS  - 2
SP  - 1-12
EP  - 1-12
PB  - MDPI
SN  - 1010660X
KW  - oropharyngeal cancer
KW  - oral cavity cancer
KW  - HPV
KW  - RAD51
KW  - radiotherapy
UR  - https://www.mdpi.com/1648-9144/59/2/361
N2  - Introduction: The incidence of advanced oral cavity and oropharyngeal cancers is generally high. Treatment outcomes for patients, especially those unfit for comprehensive cancer treatment, are unsatisfactory. Therefore, the search for factors to predict response to treatment and increase overall survival is underway. Objective: This study aimed to analyze the presence of 32 HPV genotypes in tumor samples of 34 patients and the effect of HPV status and RAD51 on overall survival. Method: Tumor samples of 34 patients with locally advanced oropharyngeal or oral cavity cancer treated with accelerated radiotherapy in monotherapy were analyzed using reverse hybridization and immunohistochemistry for the presence of HPV and RAD51. Its effect on overall survival was examined. Results: Only two types of HPV were identified-HPV 16 (dominant) and HPV 66 (two samples). The HPV positivity was associated with a borderline insignificant improvement in 2-year (p = 0.083), 5-year (p = 0.159), and overall survival (p = 0.083). Similarly, the RAD51 overexpression was associated with borderline insignificant improvement in 2-year (p = 0.083) and 5-year (p = 0.159) survival. Conclusion: We found no statistically significant differences but detected trends toward improvement in the survival of HPV-positive and RAD51 overexpressing patients unfit for surgical treatment or chemotherapy treated with hyperfractionated radiotherapy. The trends, however, indicate that in a larger group of patients, the effects of these two parameters would likely be statistically significant.
ER  -

ZDEBLOVA CERMAKOVA, Zuzana, Pavel HURNÍK, David KONVALINKA, Jan STEMBIREK, Tereza PARACKOVA, Kamila RESOVA, Jakub CVEK, Tomas BLAZEK, Lukas KNYBEL, Martin FORMANEK, Mariam GACHECHILADZE, Markus JOERGER, Alex SOLTERMANN, Jozef SKARDA, Oldrich MOTYKA a Jana JANOUTOVA. HPV and RAD51 as Prognostic Factors for Survival in Inoperable Oral and Oropharyngeal Cancer in Patients Unfit for Chemotherapy Treated with Hyperfractionated Radiotherapy. \textit{Medicina-Lithuania}. Basel: MDPI, 2023, roč.~59, č.~2, s.~1-12. ISSN~1010-660X. Dostupné z: https://dx.doi.org/10.3390/medicina59020361.

Podrobný výpis o publikaci